申请人:Nissan Chemical Industries, Ltd.
公开号:EP3085695A1
公开(公告)日:2016-10-26
It is an object to provide a novel triazinone compound which has an inhibitory activity on a T-type voltage-dependent calcium channel, and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. A novel triazinone compound of Formula (I):
wherein each substituent in the formula is defined in detail in the description, R4 means a hydrogen atom, or a C1-6 alkoxy group, etc., L1 and L2 each independently mean a single bond, or NR2, etc., L3 means a C1-6 alkylene group, etc., A means a C6-14 aryl group or a 5 to 10-membered heteroaryl group which may be substututed, B means a C3-11 cycloalkylene group, etc., D means a C6-14 aryl amino group or a 5 to 10-membered heteroaryl group which may be substituted, etc., a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, or the pharmaceutically acceptable salt.
提供一种新型三嗪酮化合物,其具有对T型电压依赖性钙通道的抑制活性,特别适用于预防或治疗疼痛、慢性肾病和房颤。公式(I)中的新型三嗪酮化合物:其中公式中的每个取代基在描述中有详细定义,R4表示氢原子或C1-6烷氧基等,L1和L2各自独立表示单键或NR2等,L3表示C1-6烷基等,A表示C6-14芳基或5至10环杂芳基,可取代,B表示C3-11环烷基等,D表示C6-14芳胺基或5至10环杂芳基,可取代等,化合物的互变异构体,化合物的药用可接受盐,化合物的溶剂化合物,互变异构体或药用可接受盐。